What does the drug do?

Triumeq is a drug that is used to treat patients with the human immunodeficiency virus (HIV) and is shown to be safe. It is thought that ancient viruses (retroviruses) have left their genetic material in our DNA during the human evolution. In some people, this old genetic material may become activated and is believed to be a cause of MND.


The Phase 2 trial (called Lighthouse), showed that Triumeq could suppress this genetic reactivation and may slow disease progression in people living with ALS. Triumeq was shown to be safe and well tolerated in people living with ALS. You can read more about this trial here.


The Phase 3 trial called Lighthouse II is a randomized, double-blind, placebo-controlled study. This means that participants will be randomly allocated to receive a treatment with either Triumeq or a placebo (dummy drug). This is a much larger trial than Lighhouse, expecting to enroll 390 participants, who will take triumeq for a maximum of 24 months. You can find out more about the trial here.

The trial is currently recruiting at the following sites:

The trial is currently in preparation at the following sites:

  • Liverpool
  • Sheffield
  • Preston

Latest News

September 2022 - The trial began recruiting in the UK.


Want to find out more about Triumeq? Check out the resources below:


Could MND be treated by HIV drugs?

Lighthouse Project shines a beacon on HERVs and their role in ALS

Last updated: 06/09/2022